Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALIST: Dulaglutide for NASH in T2DM
NCT03648554Phase 4Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of dulaglutide biosimilar 14028 injection in Nonalcoholic steatohepatitis (NASH), sponsored by CHRU de Nancy - Hôpital Central. Status: unknown.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03648554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648554.